Efficacy and safety of high-dose GLP-1, GLP-1/GIP and GLP-1/glucagon receptor agonists in type 2 diabetes. De Block CEM, Dirinck E, Verhaegen A, Van Gaal LF, et al. Diabetes Obes Metab 2022 Jan 4. doi: 10.1111/dom.14640.

Read + Share

Amedeo Smart

Independent Medical Education

De Block CEM, Dirinck E, Verhaegen A, Van Gaal LF, et al. Efficacy and safety of high-dose GLP-1, GLP-1/GIP and GLP-1/glucagon receptor agonists in type 2 diabetes. Diabetes Obes Metab 2022 Jan 4. doi: 10.1111/dom.14640.
PMID: 34984793